Oncology Molecular Diagnostics Market Size, Share, and Outlook, H2-2025 Report- By Product (Instrument, Reagents, Others), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Ge
Description
Oncology Molecular Diagnostics Market Outlook
The global Oncology Molecular Diagnostics Market Size is valued at $3.8 Billion in 2025 and is forecast to reach $8.6 Billion in 2032 at a CAGR of 12.4%.
The Oncology Molecular Diagnostics Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Oncology Molecular Diagnostics Market segments across 22 countries from 2021 to 2032. Key segments covered include By Product (Instrument, Reagents, Others), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing, In-situ Hybridization, Mass Spectrometry, Transcription Mediated Amplification (TMA), Chips and Microarrays, Others), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, Others), By End-User (Hospitals, Diagnostic Centers, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Oncology Molecular Diagnostics Market Insights, 2025
Recent developments in the oncology molecular diagnostics market highlight advances in next-generation sequencing (NGS), digital PCR, and single-cell genomics enabling comprehensive tumor profiling and minimal residual disease detection. Integration of liquid biopsy platforms allows non-invasive monitoring of tumor evolution and early relapse detection. Artificial intelligence-powered bioinformatics tools enhance interpretation of complex genomic data, supporting precision oncology decisions. Regulatory frameworks have adapted to accommodate companion diagnostics co-developed with targeted therapies. Efforts to standardize testing protocols and quality controls are advancing to ensure reproducibility across laboratories. Expansion of multiplex panels covering actionable mutations facilitates broader patient stratification for clinical trials and treatment. Point-of-care molecular testing devices are emerging to accelerate diagnosis in community settings. Increasing collaborations between diagnostics and pharma companies streamline biomarker-driven drug development. Data privacy and interoperability considerations drive innovation in secure genomic data management.
Five Trends Shaping the Global Oncology Molecular Diagnostics Market in 2025 and Beyond
The global Oncology Molecular Diagnostics Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Oncology Molecular Diagnostics Industry?
The Oncology Molecular Diagnostics Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Oncology Molecular Diagnostics Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Oncology Molecular Diagnostics Market Segment Insights
The Oncology Molecular Diagnostics Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Product (Instrument, Reagents, Others), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing, In-situ Hybridization, Mass Spectrometry, Transcription Mediated Amplification (TMA), Chips and Microarrays, Others), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, Others), By End-User (Hospitals, Diagnostic Centers, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Oncology Molecular Diagnostics Industry Value Chain
The chapter identifies potential companies and their operations across the global Oncology Molecular Diagnostics Industry ecosystem. It assists decision-makers in evaluating global Oncology Molecular Diagnostics Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Oncology Molecular Diagnostics Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Oncology Molecular Diagnostics Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Oncology Molecular Diagnostics Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Oncology Molecular Diagnostics Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Oncology Molecular Diagnostics Market.
Europe Oncology Molecular Diagnostics Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Oncology Molecular Diagnostics Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Oncology Molecular Diagnostics Industry competitiveness. The report analyses the key Oncology Molecular Diagnostics Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Oncology Molecular Diagnostics Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Oncology Molecular Diagnostics Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Oncology Molecular Diagnostics Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Oncology Molecular Diagnostics Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Oncology Molecular Diagnostics Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Oncology Molecular Diagnostics Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Abbott Laboratories, Agilient Technologies Inc, bioMérieux SA, Danaher Corp, F. Hoffmann La-Roche Ltd, HTG Molecular Diagnostics Inc, Illumina Inc, QIAGEN N.V., Sysmex Corp, TBG Diagnostics Ltd, Thermo Fisher Scientific Inc, Veracyte Inc. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Oncology Molecular Diagnostics Market Scope
Leading Segments
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
Leading Companies
Abbott Laboratories
Agilient Technologies Inc
bioMérieux SA
Danaher Corp
F. Hoffmann La-Roche Ltd
HTG Molecular Diagnostics Inc
Illumina Inc
QIAGEN N.V.
Sysmex Corp
TBG Diagnostics Ltd
Thermo Fisher Scientific Inc
Veracyte Inc
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Oncology Molecular Diagnostics Market Size is valued at $3.8 Billion in 2025 and is forecast to reach $8.6 Billion in 2032 at a CAGR of 12.4%.
The Oncology Molecular Diagnostics Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Oncology Molecular Diagnostics Market segments across 22 countries from 2021 to 2032. Key segments covered include By Product (Instrument, Reagents, Others), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing, In-situ Hybridization, Mass Spectrometry, Transcription Mediated Amplification (TMA), Chips and Microarrays, Others), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, Others), By End-User (Hospitals, Diagnostic Centers, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Oncology Molecular Diagnostics Market Insights, 2025
Recent developments in the oncology molecular diagnostics market highlight advances in next-generation sequencing (NGS), digital PCR, and single-cell genomics enabling comprehensive tumor profiling and minimal residual disease detection. Integration of liquid biopsy platforms allows non-invasive monitoring of tumor evolution and early relapse detection. Artificial intelligence-powered bioinformatics tools enhance interpretation of complex genomic data, supporting precision oncology decisions. Regulatory frameworks have adapted to accommodate companion diagnostics co-developed with targeted therapies. Efforts to standardize testing protocols and quality controls are advancing to ensure reproducibility across laboratories. Expansion of multiplex panels covering actionable mutations facilitates broader patient stratification for clinical trials and treatment. Point-of-care molecular testing devices are emerging to accelerate diagnosis in community settings. Increasing collaborations between diagnostics and pharma companies streamline biomarker-driven drug development. Data privacy and interoperability considerations drive innovation in secure genomic data management.
Five Trends Shaping the Global Oncology Molecular Diagnostics Market in 2025 and Beyond
The global Oncology Molecular Diagnostics Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Oncology Molecular Diagnostics Industry?
The Oncology Molecular Diagnostics Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Oncology Molecular Diagnostics Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Oncology Molecular Diagnostics Market Segment Insights
The Oncology Molecular Diagnostics Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Product (Instrument, Reagents, Others), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing, In-situ Hybridization, Mass Spectrometry, Transcription Mediated Amplification (TMA), Chips and Microarrays, Others), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, Others), By End-User (Hospitals, Diagnostic Centers, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Oncology Molecular Diagnostics Industry Value Chain
The chapter identifies potential companies and their operations across the global Oncology Molecular Diagnostics Industry ecosystem. It assists decision-makers in evaluating global Oncology Molecular Diagnostics Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Oncology Molecular Diagnostics Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Oncology Molecular Diagnostics Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Oncology Molecular Diagnostics Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Oncology Molecular Diagnostics Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Oncology Molecular Diagnostics Market.
Europe Oncology Molecular Diagnostics Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Oncology Molecular Diagnostics Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Oncology Molecular Diagnostics Industry competitiveness. The report analyses the key Oncology Molecular Diagnostics Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Oncology Molecular Diagnostics Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Oncology Molecular Diagnostics Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Oncology Molecular Diagnostics Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Oncology Molecular Diagnostics Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Oncology Molecular Diagnostics Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Oncology Molecular Diagnostics Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Abbott Laboratories, Agilient Technologies Inc, bioMérieux SA, Danaher Corp, F. Hoffmann La-Roche Ltd, HTG Molecular Diagnostics Inc, Illumina Inc, QIAGEN N.V., Sysmex Corp, TBG Diagnostics Ltd, Thermo Fisher Scientific Inc, Veracyte Inc. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Oncology Molecular Diagnostics Market Scope
Leading Segments
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
Leading Companies
Abbott Laboratories
Agilient Technologies Inc
bioMérieux SA
Danaher Corp
F. Hoffmann La-Roche Ltd
HTG Molecular Diagnostics Inc
Illumina Inc
QIAGEN N.V.
Sysmex Corp
TBG Diagnostics Ltd
Thermo Fisher Scientific Inc
Veracyte Inc
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
183 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Oncology Molecular Diagnostics Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Oncology Molecular Diagnostics Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Oncology Molecular Diagnostics Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Oncology Molecular Diagnostics Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Oncology Molecular Diagnostics Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Product
- Instrument
- Reagents
- Others
- By Technology
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- DNA Sequencing and Next-Generation Sequencing
- In-situ Hybridization
- Mass Spectrometry
- Transcription Mediated Amplification (TMA)
- Chips and Microarrays
- Others
- By Application
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer
- Liver Cancer
- Cervical Cancer
- Others
- By End-User
- Hospitals
- Diagnostic Centers
- Others
- 6. Global Oncology Molecular Diagnostics Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Oncology Molecular Diagnostics Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Oncology Molecular Diagnostics Market Trends and Growth Opportunities
- 6.2.1 North America Oncology Molecular Diagnostics Market Outlook by Type
- 6.2.2 North America Oncology Molecular Diagnostics Market Outlook by Application
- 6.3 North America Oncology Molecular Diagnostics Market Outlook by Country
- 6.3.1 The US Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 6.3.2 Canada Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 6.3.3 Mexico Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7. Europe Oncology Molecular Diagnostics Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Oncology Molecular Diagnostics Market Trends and Growth Opportunities
- 7.2.1 Europe Oncology Molecular Diagnostics Market Outlook by Type
- 7.2.2 Europe Oncology Molecular Diagnostics Market Outlook by Application
- 7.3 Europe Oncology Molecular Diagnostics Market Outlook by Country
- 7.3.2 Germany Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7.3.3 France Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7.3.4 The UK Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7.3.5 Spain Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7.3.6 Italy Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7.3.7 Russia Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8. Asia Pacific Oncology Molecular Diagnostics Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Oncology Molecular Diagnostics Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Oncology Molecular Diagnostics Market Outlook by Type
- 8.2.2 Asia Pacific Oncology Molecular Diagnostics Market Outlook by Application
- 8.3 Asia Pacific Oncology Molecular Diagnostics Market Outlook by Country
- 8.3.1 China Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8.3.2 India Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8.3.3 Japan Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8.3.4 South Korea Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8.3.5 Australia Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8.3.6 South East Asia Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 9. South America Oncology Molecular Diagnostics Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Oncology Molecular Diagnostics Market Trends and Growth Opportunities
- 9.2.1 South America Oncology Molecular Diagnostics Market Outlook by Type
- 9.2.2 South America Oncology Molecular Diagnostics Market Outlook by Application
- 9.3 South America Oncology Molecular Diagnostics Market Outlook by Country
- 9.3.1 Brazil Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 9.3.2 Argentina Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 10. Middle East and Africa Oncology Molecular Diagnostics Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Oncology Molecular Diagnostics Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Oncology Molecular Diagnostics Market Outlook by Type
- 10.2.2 Middle East and Africa Oncology Molecular Diagnostics Market Outlook by Application
- 10.3 Middle East and Africa Oncology Molecular Diagnostics Market Outlook by Country
- 10.3.1 Saudi Arabia Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 10.3.2 The UAE Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 10.3.4 South Africa Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 10.3.5 Egypt Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Oncology Molecular Diagnostics Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Abbott Laboratories
- Agilient Technologies Inc
- bioMérieux SA
- Danaher Corp
- F. Hoffmann La-Roche Ltd
- HTG Molecular Diagnostics Inc
- Illumina Inc
- QIAGEN N.V.
- Sysmex Corp
- TBG Diagnostics Ltd
- Thermo Fisher Scientific Inc
- Veracyte Inc
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
